A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus

Allen, E. R. et al. (2018) A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus. Cell Reports, 25(13), 3750-3758.e4. (doi:10.1016/j.celrep.2018.12.001) (PMID:30590046) (PMCID:PMC6315105)

Allen, E. R. et al. (2018) A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus. Cell Reports, 25(13), 3750-3758.e4. (doi:10.1016/j.celrep.2018.12.001) (PMID:30590046) (PMCID:PMC6315105)

[img]
Preview
Text
177724.pdf - Published Version
Available under License Creative Commons Attribution.

3MB

Abstract

The Gn subcomponent of the Gn-Gc assembly that envelopes the human and animal pathogen, Rift Valley fever virus (RVFV), is a primary target of the neutralizing antibody response. To better understand the molecular basis for immune recognition, we raised a class of neutralizing monoclonal antibodies (nAbs) against RVFV Gn, which exhibited protective efficacy in a mouse infection model. Structural characterization revealed that these nAbs were directed to the membrane-distal domain of RVFV Gn and likely prevented virus entry into a host cell by blocking fusogenic rearrangements of the Gn-Gc lattice. Genome sequence analysis confirmed that this region of the RVFV Gn-Gc assembly was under selective pressure and constituted a site of vulnerability on the virion surface. These data provide a blueprint for the rational design of immunotherapeutics and vaccines capable of preventing RVFV infection and a model for understanding Ab-mediated neutralization of bunyaviruses more generally.

Item Type:Articles
Additional Information:T.A.B. and K.J.D. are supported by the Medical Research Council (MR/L009528/1, MR/K024426/1, and MR/N002091/1) and Wellcome (089026/Z/09/Z to T.A.B.). G.M.W. is supported through an Oak Foundation Fellowship. This study is published with the permission of the Director of the Kenya Medical Research Institute. O.G.P. was funded by the European Research Council under FP7/2007-2013/European Research Council grant agreement 614725-PATHPHYLODYN. S.H. and J.T.H. are supported by European Research Council under the European Union’s Horizon 2020 research and innovation program (649053). The Wellcome Centre for Human Genetics is supported by grant 203141/Z/16/Z. E.R.A. is the recipient of a PHE PhD studentship.
Keywords:Rift Valley fever virus, antibody, antiviral, bunyavirus, immune response, neutralization, phlebovirus, structure, vaccine, virus-host interactions.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Elliott, Mrs Angela and Koudriakova, Elina and Brennan, Dr Benjamin and Elliott, Professor Richard
Authors: Allen, E. R., Krumm, S. A., Raghwani, J., Halldorsson, S., Elliott, A., Graham, V. A., Koudriakova, E., Harlos, K., Wright, D., Warimwe, G. M., Brennan, B., Huiskonen, J. T., Dowall, S. D., Elliott, R. M., Pybus, O. G., Burton, D. R., Hewson, R., Doores, K. J., and Bowden, T. A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Cell Reports
Publisher:Elsevier (Cell Press)
ISSN:2211-1247
ISSN (Online):2211-1247
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Cell Reports 25(13): 3750-3758.e4
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record